Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Katie LeachArthur Christopoulos

Abstract

We recently identified LY2033298 as a novel allosteric potentiator of acetylcholine (ACh) at the M(4) muscarinic acetylcholine receptor (mAChR). This study characterized the molecular mode of action of this modulator in both recombinant and native systems. Radioligand-binding studies revealed that LY2033298 displayed a preference for the active state of the M(4) mAChR, manifested as a potentiation in the binding affinity of ACh (but not antagonists) and an increase in the proportion of high-affinity agonist-receptor complexes. This property accounted for the robust allosteric agonism displayed by the modulator in recombinant cells in assays of [(35)S]GTPgammaS binding, extracellular regulated kinase 1/2 phosphorylation, glycogen synthase kinase 3beta phosphorylation, and receptor internalization. We also found that the extent of modulation by LY2033298 differed depending on the signaling pathway, indicating that LY2033298 engenders functional selectivity in the actions of ACh. This property was retained in NG108-15 cells, which natively express rodent M(4) mAChRs. Functional interaction studies between LY2033298 and various orthosteric and allosteric ligands revealed that its site of action overlaps with the allosteric site use...Continue Reading

References

Feb 1, 1983·British Journal of Pharmacology·N J BirdsallM J Zigmond
Jan 1, 1996·Annual Review of Pharmacology and Toxicology·J Black
Mar 1, 1997·Alzheimer Disease and Associated Disorders·A J LernerR P Friedland
Aug 17, 1999·Biochemical Pharmacology·A Christopoulos, E E El-Fakahany
Sep 1, 1999·Proceedings of the National Academy of Sciences of the United States of America·J GomezaJ Wess
Nov 19, 2002·Molecular Pharmacology·S LazarenoN J M Birdsall
Nov 5, 2003·Proceedings of the National Academy of Sciences of the United States of America·Cyrille SurP Jeffrey Conn
Jan 28, 2004·Nature Genetics·Effat S EmamianJoseph A Gogos
Mar 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·Jean-Martin BeaulieuMarc G Caron
Jul 3, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Eleni T TzavaraGeorge G Nomikos
Aug 31, 2004·The Journal of Pharmacology and Experimental Therapeutics·Lauren T MayArthur Christopoulos
Nov 4, 2004·Biological Psychiatry·Masashi IkedaNorio Ozaki
Jul 26, 2005·Journal of Neuroscience Research·Chao Deng, Xu-Feng Huang
Oct 19, 2005·British Journal of Pharmacology·Lauren T MayArthur Christopoulos
May 20, 2006·Molecular Pharmacology·Alfred A LanzafameArthur Christopoulos
Jun 29, 2006·The Journal of Pharmacology and Experimental Therapeutics·Jonathan D UrbanRichard B Mailman
Aug 8, 2006·Trends in Pharmacological Sciences·Christopher J Langmead, Arthur Christopoulos
Oct 3, 2006·Annual Review of Pharmacology and Toxicology·Lauren T MayArthur Christopoulos
Oct 3, 2006·Current Opinion in Neurobiology·Michael E Hasselmo
Dec 29, 2006·Journal of Molecular Neuroscience : MN·M E Hasselmo, L M Giocomo
Feb 28, 2007·Trends in Neurosciences·Simon LovestoneRobin Murray
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Blaine N ArmbrusterBryan L Roth
May 26, 2007·Molecular Pharmacology·Lauren T MayArthur Christopoulos
Jul 17, 2007·Trends in Pharmacological Sciences·Katie LeachArthur Christopoulos
Sep 1, 2007·Nature Reviews. Drug Discovery·Jürgen WessDinesh Gautam
Dec 7, 2007·Nature Chemical Biology·Jana K ShireyP Jeffrey Conn
Jul 3, 2008·The American Journal of Psychiatry·Anantha ShekharChristian C Felder

❮ Previous
Next ❯

Citations

Feb 13, 2013·ACS Chemical Neuroscience·J Robert LaneMeritxell Canals
Oct 1, 2013·Journal of Medicinal Chemistry·Tracey HuynhBen Capuano
Feb 11, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Martilias Farrell, Bryan L Roth
Oct 1, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Carrie K JonesMichael Bubser
Nov 17, 2011·The Journal of Biological Chemistry·Meritxell CanalsArthur Christopoulos
Aug 12, 2014·Nature Chemical Biology·J Robert LaneArthur Christopoulos
Sep 2, 2014·Nature Reviews. Drug Discovery·P Jeffrey ConnColleen M Niswender
Sep 14, 2011·Annual Review of Pharmacology and Toxicology·Celine ValantArthur Christopoulos
Sep 28, 2010·Annual Review of Pharmacology and Toxicology·John A Allen, Bryan L Roth
May 1, 2015·Expert Opinion on Drug Discovery·Rumin Zhang, Michael Kavana
Sep 21, 2013·Drug Discovery Today. Technologies·María Kimatrai-SalvadorRomeo Romagnoli
Nov 28, 2012·Trends in Pharmacological Sciences·J Robert LaneArthur Christopoulos
May 31, 2012·Pharmacology & Therapeutics·Frederick J Mitchelson
Jun 28, 2011·Current Opinion in Pharmacology·David G Trist
Jul 20, 2010·Neuropharmacology·Peter KeovArthur Christopoulos
Feb 13, 2014·British Journal of Pharmacology·Stephen P H AlexanderUNKNOWN CGTP Collaborators
Apr 1, 2014·Current Opinion in Cell Biology·Christopher J Langmead, Arthur Christopoulos
Oct 1, 2013·Neurobiology of Disease·Hilary Highfield Nickols, P Jeffrey Conn
Jul 27, 2010·Molecular and Cellular Endocrinology·Nicola J SmithGraeme Milligan
May 9, 2015·Cancer Metastasis Reviews·Ye LingXiang-dong Wang
May 25, 2015·Neuroscience and Biobehavioral Reviews·Sean P CarruthersSusan L Rossell
Mar 15, 2011·Trends in Pharmacological Sciences·Terry Kenakin, Arthur Christopoulos
Dec 4, 2014·Trends in Pharmacological Sciences·Jesús Giraldo
Oct 17, 2012·The International Journal of Neuropsychopharmacology·Elizabeth Scarr
Jul 28, 2016·Molecular Pharmacology·Alice E BerizziArthur Christopoulos
Jan 21, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Nellie E ByunCarrie K Jones

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here